TCTMD -- Even before prasugrel was approved by the US Food and Drug Administration (FDA) last year for use in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI), concerns were raised regarding a possible increased risk of cancer with the drug. Now, in a review of unpublished data that appears in the June 28, 2010, issue of Archives of Internal Medicine, clinicians and researchers bring this concern to the forefront again and suggest that the cancer risk is higher than initially thought.
